NCT00410696 is a Phase 2 clinical trial of Filgrastim in Hematological Neoplasms, sponsored by Armando Santoro, MD.

Who is sponsoring NCT00410696?

NCT00410696 is sponsored by Armando Santoro, MD.

What drugs are being tested in NCT00410696?

Interventions in NCT00410696: Filgrastim, Pegfilgrastim.

What condition does NCT00410696 study?

NCT00410696 studies Hematological Neoplasms, Tumors.

Is NCT00410696 still recruiting?

NCT00410696 is currently completed. Last updated 28 June 2013.

Last reviewed 2013-06-28 · How we verify

NCT00410696

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy With Peripheral Autologous Stem Cell Reinfusion in Patients With Hematological Neoplasms and Solid Tumors: Phase II Randomised Trial

Completed Phase 2 Last updated 28 June 2013

What this trial tests

Phase 2 trial testing Filgrastim in Hematological Neoplasms in 80 participants. Completed in 1 November 2008.

Timeline

1 September 2006

Primary endpoint
1 November 2008

1 November 2008

Quick facts

Lead sponsor	Armando Santoro, MD
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 September 2006
Primary completion	1 November 2008
Estimated completion	1 November 2008
Sites	1 location across Italy

Drugs / interventions tested

Filgrastim — full drug profile →
Pegfilgrastim (PEGFILGRASTIM) — full drug profile →

Conditions studied

Hematological Neoplasms — all drugs for Hematological Neoplasms →
Tumors — all drugs for Tumors →

Sponsor

Armando Santoro, MD — full company profile →

Who can join

18 and older, any sex, with Hematological Neoplasms or Tumors. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Duration of aplasia period
Time frame: At time of discharge from Unit

Sponsor's own description

The primary objective of the study is to evaluate the efficacy and the safety of pegfilgrastim versus filgrastim, administered after high-dose chemotherapy and peripheral stem cell reinfusion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Filgrastim

Trials testing the same drug.

NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
NCT07278856 — Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07224100 — Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom · Phase 2 · recruiting

Other recruiting trials for Hematological Neoplasms

Currently open trials in the same condition.

NCT06904066 — Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W · Phase 1 · recruiting
NCT07085065 — Distraction With Virtual Reality From Pain and Anxiety for Patients With Hematological Malignancies · NA · recruiting
NCT03844360 — Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00410696 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Armando Santoro, MD
Last refreshed: 28 June 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00410696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing